Table 3.
Medical Therapy During Holter Recording
| Baseline PCI (N=149) | Baseline MED (N=149) | 1 Year PCI (N=131) | 1 Year MED (N=138) | |
|---|---|---|---|---|
| ACE inhibitor, n(%) | 120(80.5) | 121(81.2) | 97(74.0) | 109(79.0) |
| Angiotensin receptor blocker, n(%) | 5(3.4) | 3(2.0) | 9(6.9) | 10(7.2) |
| Beta-blocker, n(%) | 133(89.3) | 138(92.6) | 116(88.5) | 128(92.8) |
| Calcium channel blocker, n(%) | 8(5.4) | 11(7.4) | 7(5.3) | 15(10.9) |
| Digoxin, n(%) | 1(0.7) | 3(2.0) | 0(0.0) | 2(1.4) |
| Diuretic, n(%) | 24(16.1) | 30(20.1) | 25(19.1) | 35(25.4) |
| Spironolactone, n(%) | 6(4.0) | 10(6.7) | 8(6.1) | 10(7.2) |
| Class I or III anti-arrhythmic, n(%) | 2(1.3) | 4(2.7) | 4(3.1) | 2(1.4) |